Chronic Immune Thrombocytopenia Purpura Following COVID-19 Vaccination (ChAdOx1 -nCov-19): A Case Report With OneYear Follow-Up.

IF 0.8 Q4 PHARMACOLOGY & PHARMACY Hospital Pharmacy Pub Date : 2024-10-01 Epub Date: 2024-04-27 DOI:10.1177/00185787241245914
Merrin Mathew, Rovin M Theempalangad, Juny Sebastian, M D Ravi
{"title":"Chronic Immune Thrombocytopenia Purpura Following COVID-19 Vaccination (ChAdOx1 -nCov-19): A Case Report With OneYear Follow-Up.","authors":"Merrin Mathew, Rovin M Theempalangad, Juny Sebastian, M D Ravi","doi":"10.1177/00185787241245914","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Immune Thrombocytopenia Purpura (ITP) is a hematological disorder, where its primary cause is unknown. This can be triggered through any secondary underlying diseases or other environmental agents such as drugs, vaccination, natural viral infections etc. After the introduction of COVID-19 vaccines, a 4-fold increase in ITP cases was observed globally. Many of the COVID-19 vaccines such as m-RNA and viral-vector vaccines already demonstrated a cause-effect relationship between the event of ITP and immunization. <b>Case presentation:</b> A 54 year old diabetic patient presented to the hospital with complaints of gum bleeding and fatigue. He was diagnosed with severe ITP following COVID-19 vaccination with a platelet count of 5000 cumm. Initially his condition was considered as idiopathic and the COVID-19 vaccine exposure (13 days prior to the clinical presentation) was not suspected. Later the immunization timeline and onset of the reaction was traced by his hematologist. The patient underwent multiple platelet transfusions and was given corticosteroid therapy. The patient was followed for a period of 1 year and throughout the follow-up period the patient had fluctuating platelets count, especially after tapering steroids. <b>Conclusion:</b> ITP in this case is found to have a consistent causal association to COVID-19 vaccination as per the World Health Organization Causality assessment algorithm and is categorized under vaccine product related reactions. One year follow-up conducted showed that the thrombocytopenia following COVID-19 vaccine may be prolonged.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418665/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00185787241245914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immune Thrombocytopenia Purpura (ITP) is a hematological disorder, where its primary cause is unknown. This can be triggered through any secondary underlying diseases or other environmental agents such as drugs, vaccination, natural viral infections etc. After the introduction of COVID-19 vaccines, a 4-fold increase in ITP cases was observed globally. Many of the COVID-19 vaccines such as m-RNA and viral-vector vaccines already demonstrated a cause-effect relationship between the event of ITP and immunization. Case presentation: A 54 year old diabetic patient presented to the hospital with complaints of gum bleeding and fatigue. He was diagnosed with severe ITP following COVID-19 vaccination with a platelet count of 5000 cumm. Initially his condition was considered as idiopathic and the COVID-19 vaccine exposure (13 days prior to the clinical presentation) was not suspected. Later the immunization timeline and onset of the reaction was traced by his hematologist. The patient underwent multiple platelet transfusions and was given corticosteroid therapy. The patient was followed for a period of 1 year and throughout the follow-up period the patient had fluctuating platelets count, especially after tapering steroids. Conclusion: ITP in this case is found to have a consistent causal association to COVID-19 vaccination as per the World Health Organization Causality assessment algorithm and is categorized under vaccine product related reactions. One year follow-up conducted showed that the thrombocytopenia following COVID-19 vaccine may be prolonged.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接种 COVID-19 疫苗 (ChAdOx1 -nCov-19) 后出现慢性免疫性血小板减少紫癜:随访一年的病例报告。
背景:免疫性血小板减少性紫癜(ITP免疫性血小板减少紫癜(ITP)是一种主因不明的血液病。任何继发性基础疾病或其他环境因素(如药物、疫苗接种、自然病毒感染等)都可能诱发这种疾病。COVID-19 疫苗问世后,全球的 ITP 病例增加了 4 倍。许多 COVID-19 疫苗(如 m-RNA 和病毒载体疫苗)已经证明,ITP 事件与免疫接种之间存在因果关系。病例介绍:一名 54 岁的糖尿病患者因牙龈出血和乏力到医院就诊。接种 COVID-19 疫苗后,他被诊断为严重的 ITP,血小板计数为 5000 cumm。起初,他的病情被认为是特发性的,并未怀疑接触过 COVID-19 疫苗(临床表现前 13 天)。后来,他的血液科医生追查到了免疫时间线和反应的起始时间。患者接受了多次血小板输注和皮质类固醇治疗。对患者进行了为期 1 年的随访,在整个随访期间,患者的血小板计数波动较大,尤其是在减量使用类固醇后。结论根据世界卫生组织的因果关系评估算法,该病例中的 ITP 与接种 COVID-19 疫苗有一致的因果关系,属于疫苗产品相关反应。一年的随访显示,接种 COVID-19 疫苗后血小板减少的时间可能会延长。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hospital Pharmacy
Hospital Pharmacy PHARMACOLOGY & PHARMACY-
CiteScore
1.70
自引率
0.00%
发文量
63
期刊介绍: Hospital Pharmacy is a monthly peer-reviewed journal that is read by pharmacists and other providers practicing in the inpatient and outpatient setting within hospitals, long-term care facilities, home care, and other health-system settings The Hospital Pharmacy Assistant Editor, Michael R. Cohen, RPh, MS, DSc, FASHP, is author of a Medication Error Report Analysis and founder of The Institute for Safe Medication Practices (ISMP), a nonprofit organization that provides education about adverse drug events and their prevention.
期刊最新文献
Cefepime/Enmetazobactam. Impact of a Medication Reconciliation Improvement Package on Adherence to Medication Reconciliation Among Internal Medicine Physicians: A Quality Improvement Project in a Lower-Middle Income Country. Implementing Research Into Practice as a Clinical Based New Practitioner Pharmacist. Phytonadione Utilization and the Risk of Bleeding in Chronic Liver Disease. Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1